Poster Session A  
Tuesday, December 2, 2014, 1:15-3:30 p.m.

Antibody Effector Mechanisms in Immune Therapy

A01  Ex vivo evaluation of an anti-Müllerian hormone type II receptor humanized antibody with optimized Fc effector function in ovarian cancer.  Houcine Bougherara, Fariba Némati, Christophe De Romeuf, Jean-Marc Barret, Gérald Massonnet, Marie-Aude Le Frère-Belda, Jean-François Prost, Didier Decaudin, Emmanuel Donnadieu.

A02  The art of omission: Low fucose antibodies enhance tumor cell clearance in vivo.  Rens Braster, Remco Visser, Gestur Vidarsson, Marjolein van Egmond.


A04  Systemic agonistic anti-CD40 treatment of tumor bearing mice modulates hepatic myeloid suppressive cells and causes immune-mediated liver damage.  Jose Medina-Echeverz, Chi Ma, Tobias Eggert, Tim F Greten.

A05  Combining the long-acting engineered cytokine NKTR-214 with checkpoint inhibitors is synergistic and shows long lasting anti-tumor immunity in murine tumor models.  Seema Kantak, Rhoneil Pena, Murali Addepalli, Steve Lee, Kirksey Yolanda, Rupesh Kanhere, Priyam Jha, Ute Hoch, Deborah Charych, Stephen K Doberstein.

A06  Identification and characterization of a potent anti-human TIM-3 antagonist.  Jean da Sliva Correia, Marilyn Kehry, Margaret Marino, Haley Laken, David J King.

A07  Combining CTLA4 and PD-L1 blockade leads to complete eradication of metastatic osteosarcoma.  Danielle M Lussier, John L Johnson, Pooja Hingorani, Joseph N Blattman.

A08  Distribution, cutoff, and functional significance of a potential biomarker for Imprime PGG, an experimental cancer immunotherapeutic, in a healthy subject population.  Diane McMurray, Ben Harrison, Katie Ertelt, Richard Walsh, Lindsay Wurst, Steven Leonardo, Nadine Ottoson, Adria Bykowski Jonas, Xiaohong Qiu, Nandita Bose, Peter Maimonis.


A10  Soluble CD25 and C-reactive protein predict overall survival in melanoma patients receiving anti-CD40 monoclonal antibody CP-870,893 (aCD40) and anti-CTLA4 monoclonal antibody tremelimunab.  Rosemarie Mick, David Bajor, Lee Richman, Robert Vonderheide.
A11 Activity of a bispecific antibody targeting EGFR and cMet with enhanced Fc effector function in EGFR mutant setting with cMet pathway activation. Keri L Soring, Katharine D Grugan, Randall J Breszki, Jose Pardinas, Leopoldo Luistro, Barbara Bushey, Joost Neijssen, Paul Parren, Janine Schuurman, Mark Anderson, Ricardo Attar, Matthew V Lorenzi, Mark Chiu, Sheri Moores.


A13 Humanized mouse models for in vivo evaluation of anti-human cancer immunotherapeutics. Juan Zhang, Meng Qiao, Qian Shi.

A14 Overcoming therapeutic MAb resistance in aggressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells. Sandrine Valsesia-Wittmann, Beatrice Clemenceau, Anne-Catherine Jallas, Jean-Yves Blay, Aurelien Marabelle, Christophe Caux, Henri Vie.


A16 High αV integrin level in melanoma cells is associated with development of brain metastasis in athymic rats. Jeffrey Wu, Michael A. Pagel, Leslie L Muldoon, Edward A. Neuwelt.

Interaction of Radiobiology

A17 The role of radiation-induced TGF-β in the generation of MDSCs. Alba Gonzalez-Junca, Ilenia Pelicciotta, Kyla Elizabeth Discroll, Mary Helen Barcellos-Hoff.


A20 A systematic evaluation of abscopal responses following radiation therapy in patients with metastatic melanoma treated with ipilimumab. Ravi A. Chandra, Tyler J. Wilhite, Tracy A. Balboni, Alexander Spektor, Andrea K. Ng, Frank Stephen Hodi, Jonathan D. Schoenfeld.

A21 Adenosine is a rheostat for radiation therapy-induced immune activation. Erik Wennerberg, Noriko Kawashima, Sandra Demaria.

Other


A30 Anti-tumor effect of natural killer cells in human PBMCs against ovarian cancer. Veethika Pandey, Jeremiah L Oyer, Robert Y Igarashi, Susan B Ingersoll, Alicja J Copik, Deborah A Altomare.


A33 Preparation of local anti-wart and anti-inflammatory rub of polyglycidol based saturated lipid (DDP-PG) with HPMC containing curcumin. Sharif Mohammad Shaheen, Pavel Bakardzhiev, Denitsa Momekova, Neli S. Koseva, Stanislav Rangelov.

A36  Novel therapeutic approaches for human malignant mesothelioma.  Haining Yang, Sandro Jube, Michele Carbone.

Overcoming Obstacles to Generating Adaptive Immunity

A37  Immunization of cutaneous melanoma patients with the allogeneic cell vaccine CSF-470 enhances immune infiltration of metastatic lesions and would favor subsequent response to Vemurafenib.  Mariana Aris, María Betina Pampena, Estrella M Levy, Alicia I Bravo, Florencia P Madorsky-Rowdo, Ana Mordoh, Julio Kaplan, Antonela Baron, Mariela Urrutia, Paula A Blanco, María Marcela Barrio, José Mordoh.


A39  Targeting tumor infiltrating myeloid cells with a potent CCR1 small molecule antagonist.  Ashley G Bischof, Joanne BL Tan, Sreenivas Punna, Penglie Zhang, Israel Charo, Anne-Marie Duliege, Thomas Schall.

A41  Galectin-9 has tumor promoting properties that may be targetable in metastatic melanoma.  Elizabeth Ann L Enninga, Wendy K Nevala, Svetomir N Markovic.

A42  MK-1775, a WEE1 inhibitor alleviates resistance to immune attack of tumor cells undergoing an epithelial-mesenchymal transition.  Duane H Hamilton, Romaine I Fernando, Kwong-Yok Tsang, Claudia Palena.


A44  Checkpoint inhibition of adaptive immunity by IL-9 can be disrupted to achieve rapid T cell sensitization and rejection of progressive tumor challenges.  Dominique B Hoelzinger, Ana Lucia Dominguez, Peter A Cohen, Sandra J Gendler.

A45  Cyclin-dependent Kinase 5 regulates gamma-interferon induced PD-L1 up-regulation in solid tumors.  Agne Petrosiute, Joseph Nthale, Gabby Valdivieso, R. Dixon Dorand, Tej Kumar Pareek, Deborah Sim Barkauskas, Jay T. Myers, John J. Letterio, Duncan Stearns, Alex Yee-Chen Huang.
A46  Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 and B16 mouse melanoma. Bruce Freimark, Jian Gong, Dan Ye, Van Nguyen, Shen Yin, Rich Archer, Chris Hughes, Jeff Hutchins, Jeff Hutchins, Alan Schroit, Rolf Brekken, Xianming Huang.


A48  Vaccine maneuvers which reverse tolerance to MUC1 requires antigenic diversity to mediate protection and delay immunoedited escape variants.  Vani Lakshminarayanan, Nitin Supekar, Dustin B McCurry, Jei Wei, Cathy S Madsen, Judy M Bradley, Latha B Pathangey, Margreet A Wolfret, Geert Jan Boons, Peter A Cohen, Sandra J Gendler.


A53  Expression of immune checkpoint modulators on CD4+ and CD8+ T cells coincides with activation during the priming phase of an allogeneic response.  Nina Chi Sabins, Benjamin Harman, Linda Barone, Sandra Santulli-Marotto.

A54  Laser-assisted intradermal delivery of Xcl1-specific fusion vaccines induces potent anti-tumor response.  Dorothea Terhorst, Dorothea Terhorst, Even Fossum, Bjarne Bogen, Sandrine Henri, Bernard Malissen.


A58  JAK1 deficiency as a novel mechanism of tumor immune escape in uterine cancer.  Yuan Ren, Yonghong Zhang, Richard Z Liu, David A Fenstermacher, Kenneth L Wright, Jamie K Teer, Jie Wu.

Tumor Microenvironment


A60  Synergistic effect of targeted chemotherapy delivery using theranostic nanoparticles and PD-L1 blockade in an orthotopic mouse pancreatic cancer model.  Erica N Bozeman, Ning Gao, Weiping Qian, Andrew Wang, Lily Yang.

A61  A clinical stage TLR5 agonist EntolimodTM activates T cell immunity against liver metastases via CXCR3-coordinated NK cell recruitment to the liver.  Craig Brackett, Bojidar Kojouharov, Jean Veith, Sandra Gollnick, Lyudmila Burdelya, Scott Abrams, Andrei Gudkov.

A62  Immune and T cell receptor heterogeneity in distinct tumors within individual melanoma patients.  Alexandre Reuben, Rodabe N Amaria, Cara Haymaker, Marie Andree Forget, Chantale Bernatchez, Pei-ling Chen, Michael Tetzlaff, Michael A Davies, Karen C Dwyer, Jennifer A Wargo, Zachary A Cooper.

A63  The role of DARC in the immunological tumor microenvironment of breast cancer.  Melissa B Davis, Michele Monteil, Rupali Hire, Elizabeth W Howerth.

A64  Chronic allergic contact dermatitis, A potent tumor promoter of Marjolin's ulcer.  Shadmehr Demehri, Trevor J Cunningham, Eva A Hurst, Andras Schaffer, David M Sheinbein, Wayne M Yokoyama.


A66  Tumor-associated neutrophils in early stage human lung cancer are not immunosuppressive, but exhibit an inflammatory phenotype and provide accessory signals for T cell activation.  Evgeniy Eruslanov, Pratik Bhojnagarwala, Jon Quatromoni, Tom Stephen, Anjana Ranganathan, Charuhas Deshpande, Tatiana Akimova, Anil Vachani, Leslie Litzky, Wayne Hancock, Jose Conejo-Garcia, Michael Feldman, Sunil Singhal, Steven Albelda.

A68  Local tumor treatments to simulate systemic antitumor immune responses. Patrick Lizotte, Mee Rie Sheen, Amy M Wen, Nicole F Steinmetz, Steven Fiering.

A69  The immunological environment in triple negative breast cancer; impact on clinical outcomes towards a prognostic clinical test. Mathieu Gigoux, Tina Gruosso, Nicholas Bertos, Sadiq Saleh, Atilla Omeroglu, Hong Zhao, Margarita Souleimanova, Sarkis Meterissian, Michael Hallett, Morag Park.


A73  Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. Seiji Oguro, Yoshinori Ino, Kazuaki Shimada, Yutaka Hatanaka, Yoshihiro Matsuno, Tomoo Kosuge, Nobuyoshi Hiraoka.

A74  Spatial organization of myeloid cells in tumor microenvironment. Minhyeok KIM, Seon Woo LEE, Suk-Jo KANG, Changwon KANG.

A75  The CD8:M2 ratio by digital multiplex gene expression permits accurate quantification of net intra-tumoral immunity within the tumor microenvironment in DLBCL. Colm Keane, Frank Vari, Mark Hertzberg, John Seymour, Kim Anh Le Cao, Devinder Gill, Rodney Hicks, Michael Green, Kristen Radford, Lyn Griffiths, Dipti Talaulikar, Maher K Gandhi.

A76  Immune mechanisms and racial disparities in colon cancer. Mohammad W Khan, Mengxi Tian, John M Carethers, Kathleen L McGuire.

A77  Differential recruitment of myeloid derived immune cells and fibroblasts to the thyroid tumor microenvironment in mouse models of papillary and follicular thyroid cancer. Lee Ann King, Sergey Novitsky, Julio Ricarte-Filho, Philip Owens, Aime T. Franco.

A79 The prognostic importance of Th1 cell infiltration in colorectal cancer and mechanisms of immune regulation. Agnes Ling, Sofia Edin, Maria L Wikberg, Åke Öberg, Richard Palmqvist.


A83 The role of Ikaros in effector and regulatory T cell homeostasis in a murine pancreatic cancer model. Nadine Nelson, Shengyan Xiang, Xiaohong Zhang, Karoly Szekeres, Ghansah Tomar.


A86 Harnessing T-cell homeostasis to diagnose and treat solid and liquid tumors. Mark Robertson-Tessi, Derek Park, Kimberly Luddy, Adam Mailloux, Pearlie K Burnette, Alexander Anderson.

A87 Myristoylated alanine rich C-kinase substrate (MARCKS) expression in lung cancer cells influences immune cell populations in tumor microenvironment in murine models. Timothy D Rohrbach, Travis D Hull, John S Jarboe, Nicholas Eustace, Yong Wang, Jessy S Deshane, Christopher D Willey.


A89 PPARγ induced TGFβ expression in myeloid cells contributes to lung cancer metastasis. Trisha R Sippel, Howard Li, Dwight Hanson, Lisa Greene, Bonnie Bullock, Joanna Poczobutt, Mary Weiser-Evans, Raphael Nemenoff.
A90 Tumor associated PDL1 expression pattern in microscopically tumor positive sentinel lymph nodes (SLN) in patients with melanoma. Ahmad A Tarhini, Jennifer A Yearley, Christopher Gibson, Uma N. M. Rao, Cindy Sander, John M Kirkwood.


A92 Small molecules targeting HMGR and HDAC in colorectal cancer. Tzu-Tang Wei, Yi-Ting Lin, Yu-Chin Lin, Ching-Chow Chen.

A93 STAT3 inhibition enhances the activity of immune checkpoint inhibitors in murine syngeneic tumor models by creating a more immunogenic tumor microenvironment. Rich Woessner, Patricia McCoon, Kirsten Bell, Rachel DuPont, Mike Collins, Deborah Lawson, Prasad Nadella, Lourdes Pablo, Corinne Reimer, Vasu Sah, Paul Lyne.
Poster Session B  
Wednesday, December 3, 2014, 12:30-2:45 p.m.

Adoptive T-Cell Therapy

B01  In vivo testing of the efficacy of glioblastoma immunotherapy using T cells expressing a humanized chimeric antigen receptor against EGFRvIII.  Alina C Boesteanu, Jennifer Brogdon, Andreas Loew, Alexandria Cogdill, Joseph Fraietta, John Scholler, Carl June, Marcela V Maus, Laura A Johnson.

B02  Construction and validation of an activating and inhibitory chimeric antigen receptor (CAR) system.  Leonardo Chicaybam, Martin Bonamino.

B03  Donor-derived EBV+CD8+ T cells transduced with a WT1-specific TCR persist long-term with minimal toxicity in patients with high-risk leukemias.  Aude Chapuis, Merav Bar, Thomas Schmitt, Hieu Nguyen, Natalie Duerkopp, Felecia Wagener, Colette Chaney, Kieu-Thu Bui, Mark Tom, Rachel Perret, Philip D Greenberg.

B04  Quantitative high throughput TCRβ chain sequencing identifies and tracks adoptively transferred CD8+ T-cell subsets in vivo.  Aude Chapuis, Cindy Desmarais, Kendall Shibuya, Felecia Wagener, Cassian Yee.

B05  A biologic screen to evaluate potential toxicity of chimeric antigen receptor modified T cells against primary normal human tissues.  Alexandria P Cogdill, Alina Boesteanu, Kathleen Haines, Joseph Fraietta, John Scholler, Andreas Loew, Pramod Thekkat, Jennifer Brogdon, Marcela V Maus, Carl June, Laura A Johnson.

B06  Imaging regulatory mechanisms that limit intratumoral CTL function in a mouse melanoma model.  Tali Feferman, Natalia G Zabolinsky, Yoav Manaster, Anat Hutzler, Guy Shakhar.


B08  Invariant NKT Cells as a platform for cancer immunotherapy with chimeric antigen receptors.  Andras Heczey, Daofeng Liu, Gengwen Tian, Ekaterina Marinova, Xiuhua Gao, Linjie Guo, John Hicks, Gianpietro Dotti, Leonid Metelitsa.

B09  PD1 blockade is able to augment NY-ESO-1 directed T cell receptor engineered adoptive human T cell therapy (ACT).  Edmund K Moon, Raghuvir Ranganathan, Linda Snyder, Yangbing Zhao, Steven M Albelda.

B10  Individual CAR-T cells, when activated via their CAR or TCR, kill tumor cells with similar kinetics and can kill multiple sequential tumor targets.  Alex J Davenport, Misty R Jenkins, Ryan S Cross, S Yong Carmen, H Miles Prince, David S Ritchie, Joseph A Trapani, Michael H Kershaw, Phillip K Darcy, Paul J Neeson.
B11  Ad-RTS-hIL-12 + veledimex regulation of IL-12 expression in advanced breast cancer (BC) and melanoma patients. John J Nemunaitis, Gerald P Linette, Haythem Ali, Francois Lebel, John A Barrett, Thomas Reed, Suma Krishnan, Jonathan Lewis.

B12  Inhibition of the transcription factor Ikaros augments the tumoricidal capacity of CD8+ T cells expressing chimeric antigen receptor. Shaun O'Brien, Rajan M Thomas, Steven M Albelda, Andrew D Wells, Liang-Chuan S Wang.


B14  CD4+CD25+ regulatory T lymphocytes: prognostic indicator of Chinese breast cancer patients receiving dentitric cells-cytokine induced killer cells infusion. Qing-Kun Song, Jun Ren, Xiao-Li Wang, Xin-Na Zhou, Hua-Bing Yang, Yu-Chen Li, Jiang-Ping Wu.


B21  Combination of adenovirus and adoptive T-cell therapy breaks tumor tolerance by recruiting immune cells to and promoting their activity in the tumor. Siri Tähtinen, Susanna Grönberg-Vähä-Koskela, Dave Lumen, Mikko Siurala, Anu J. Airaksinen, Markus Vähä-Koskela, Akseli Hemminki.

B22  A Chimeric antigen receptor (CARs) based upon a killer immunoglobulin-like receptor (KIR) triggers robust cytotoxic activity in solid tumors. Enxiu Wang, Liang-Chuan Wang, Ching-Yi Tsai, Vijay Bhoj, Steven Albelda, Edmund Moon, Michael C Milone.

B23  An effective one-two punch: Whole body irradiation in combination with anti-CD40 conditioning facilitates adoptive T cell therapy of murine neuroendocrine pancreatic cancer. Lindsay K Ward-Kavanagh, Timothy K Cooper, Todd D Schell.
Construction and validation of a RheoSwitch® (RTS®) regulated CD19 chimeric antigen receptor. Dina Schneider, Darong Wu, Paul Szymanski, Nadia Sinitsyna, Jennifer Buenviaje, Srinivas Rengarajan, Gustaf Angelborg, Catherine Tran, John Beaber, Stephen Schauer, Charles Reed, Jonathan Carson, Kristi Elliott, John Barrett, Francois Lebel, Daniel Bednarik.

Controlled production of a bispecific antibody by a genetically-modified stem cell triggers T cell activation and cytolysis in non-small cell lung carcinoma. Amy Wesa, Yumei Xiong, Tim Chan, Jeff Rosenbloom, Srinivas Rengarajan, Paul Szymanski, John A Barrett, Francois Lebel, Farzad Haerizadeh, Richard Einstein.

Biology of Vaccination

Translation of cancer vaccine strategies from mice to clinical trials. Jay A. Berzofsky, Masaki Terabe, Lauren V. Wood.

IL-12-dependent downregulation of PD-1 as a mechanism of antitumor function of CpG immune adjuvant. Jeffrey Jian, Courtney Malo, Haidong Dong.


Improving the efficacy of dendritic cell-based human papillomavirus vaccines in mice using a natural lignin-carbohydrate complex and/or synthetic lignin-like polyphenol polymers. Soichi Haraguchi, Tina Pastoor, William Guy Bradley, Akiko Tanaka.

Signal peptide mediated immunization against mouse mammary tumor virus (MMTV)-associated tumors. Ori Braitbard, Tamar Gross, Maayan Roniger, Allan Bar-Sinai, Nira Hochman, Jacob Hochman.


Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines. Sung Yong Lee, JaeJeong Shim, Kang Kyung Ho, Kye Young Lee, Chien-Fu Hung, T.-C. Wu.
B34  Signal transducing adaptor protein 2 (STAP2) has the crucial role in maintaining the CTL function of memory T cells. Daisuke Muraoka, Naohiro Seo, Tae Hayashi, Naozumi Harada, Hiroshi Shiku.

B36  mRNA and dendritic cell based immunotherapy. Kris Thielemans.


Immunometabolism and Immunoregulation


B40  Inflammatory mediators are reduced two days after a radical cystectomy in bladder cancer patients consuming immune modulating drinks. Misty Bechtel, Thomas Yankee, Seth Atchison, Jeffrey Holzbeierlein, Eugene Lee, Moben Mirza, Prabhakar Chalise, Jill Hamilton-Reeves.


B42  Cyclic dinucleotides (CDNs) activated DC and NK cells in anti-tumor immunotherapy. Juan Fu.

B43  The degree of adrenergic stress signaling regulates the severity of graft versus host disease following allogeneic hematopoietic cell transplantation. Nicholas D Leigh, Kathleen M Kokolus, Jason W-L Eng, Jingxin Qiu, George L Chen, Philip L McCarthy, Xuefang Cao, Elizabeth A Repasky.

B44  The role of CD4 T cells in murine model of NASH-promoted HCC. Chi Ma, Miaojun Han, Masaki Terabe, Jay Berzofsky, Dean Felsher, Tim Greten.

B45  Mitochondrial Ca2+ transport fine-tunes functional cross-talk between anti-tumor CD8+ T lymphocytes and natural killer cells. Roman V Uzhachenko, J Shawn Goodwin, Lino Costa, Alexander Terekhov, Menaka C Thounaojam, William H Hofmeister, Anil Shanker.

B47  Efferocytosis receptors modulate DC function in response to the tumor microenvironment.  Antoine Antoine Tanne, Shaheen Ensanyat, Nina Bhardwaj.


B49  Metabolic stress within tumors lead to exhaustion of melanoma antigen-specific CD8+ T cells.  Ying Zhang, Xiangyang Zhou, Raj Kurupati, Flavia Filisio, Abeer Hudaihed, Wynetta Giles-Davis, Hildegund CJ Ertl.


Other


B52  Humoral responses in immunotherapy treated cancer patients.  Mark Branum, Paul Algate, Christy Boozer, Po-Ying Chan-Hui, Alison Fitch, Brad Greenfield, Claire Sutherland, Kristine Swiderek.

B53  Prevention of acute colitis and colitis-associated colorectal cancer by a small molecule targeting HMG-CoA reductase (HMGR) and histone deacetylases (HDACs).  Yi-Ting Lin, Tzu-Tang Wei, Yu-Chin Lin, Jim-Min Fang, Ching-Chow Chen.


B57  NK cell-mediated cytotoxicity detection can be miniaturized by direct imaging in assay wells using a Terasaki plate format using only 100,000 effector cells (PBMC).  Srividya Sundararaman, Kinga Karacsony, Diana Roen, Jaya Ghosh, Paul V. Lehmann.

B58  Early safety assessment of single and combination therapy using TDAR.  Amy L Volk, Mindi Walker, Kerry Brosnan, Dorie Capaldi, Patricia Rafferty, Daniel Weinstock, Eva Emmell.

B59  The combined effects of piperlongumine, vitamin C, and vitamin D on Caenorhabditis elegans and Volvox carteri models.  Ashley M Winters.

B60  Humanized mouse models for preclinical testing of antitumor immune therapy.  Annika Wulf-Goldenberg, Maria Stecklum, Klaus Eckert, Iduna Fichtner, Jens Hoffmann.


Tumor Microenvironment


B63  The macrophage migration inhibitory factor promotes breast cancer metastasis through interaction with the host immune response.  Kristen Balogh, Janet Cross.

B64  CSF1R-dependent tumor-associated macrophages arise from bone marrow-derived monocytes and promote gastrointestinal stromal tumor development.  Michael J Beckman, Michael Cavnar, Adrian Seifert, Juan Santamaria-Barria, Jennifer Zhang, Adam Levy, Ferdinand Rossi, Shan Zeng, Ronald P DeMatteo.


B68  BAMLET in combination with the TLR7 agonist R848 protects against melanoma in a murine model. Lydia Dyck, Nial Harte, Kenneth Hun Mok, Kingston H.G. Mills.

B69  Activation of the IL6/STAT3 pathway in childhood ependymoma is associated with a pro-inflammatory tumor microenvironment and a poor prognosis. Andrea Griesinger, Andrew M Donson, Diane Birks, Vladimir Amani, Rebecca Josephson, Kathleen Dorris, Philip Reigan, Michael Handler, Nicholas Foreman.

B70  Combination of AT1R blockade with CD40 activation provides enhanced therapeutic efficacy for mouse pancreatic adenocarcinoma. Shiwei Han, Jelena Grahovac, Trupti Vardam, Yves Boucher.


B77  Targeted nano-immune conjugates to melanoma: Pre-clinical testing of bevacizumab targeted nab-paclitaxel.. Wendy K Nevala, Svetomir N Markovic.

CXCR4 inhibition facilitates anti-PD-1 immunotherapy by reprogramming the tumor microenvironment during sorafenib treatment in hepatocellular carcinoma. Yunching Chen, Thomas Reiberger, Rakesh Ramjiawan, Mei Rosa Ng, Tai Hato, Elizabeth C Unan, Tejaswini P Reddy, Hiroki Ochiai, Pei-Huang, Andrew X. Zhu, Rakesh K. Jain, Dan G. Duda.


Exosomes derived from ascitic fluid of patients with ovarian carcinoma induce IL-4 gene expression in T lymphocytes. Ergin Sahin, Douglas D Taylor, Cicek Gercel Taylor.

Quantitative recovery of aspartyl (asparaginyl) beta hydroxylase (HAAH) from an exosomal fraction of human sera from cancer patients. Mark A Semenuk, Eleanor B Ghanbari, Michael S Lebowitz, Hossein A Ghanbari.

Live imaging reveals hypoxia to be a limiting factor in CTL-mediated tumor rejection. Guy Shakhar, Tali Feferman, Yoav Manaster, Anat Hutzler.

Tertiary lymphoid structures in chemotherapy-treated and untreated lung squamous cell carcinoma patients. Karina Silina, Alex Soltermann, Holger Moch, Aija Line, Maries van den Broek.

The NF-κB p65 and p50 homodimer cooperate with pSTAT1 to synergistically activate iNOS transcription. Priscilla Simon, Sarah Sharman, Chunwan Lu, Dafeng Yang, Amy Paschall, Kebin Liu.

CCL2 and CXCL16 are novel biomarkers to predict cancer metastasis to bone. Qiong Song, Lihui Wang, Qiuian Chen, Xin Huang, Xin Yang, Chaonan Qian, Atsushi Mizokami, Evan T Keller, Jian Zhang, Yi Lu.

Combination therapy of reovirus and checkpoint inhibition. Shane Zaidi, Kevin Shim, Karishma Rajani, Rosa Diaz, Elizabeth Ilett, Timothy Kottke, Jill Thompson, Peter Selby, Kevin Harrington, Hardev Pandha, Alan Melcher, Matt Coffey, Richard Vile.

Characterization of melanoma metastases and the immune microenvironment by infrared imaging. Noémie Wald, Daniel E Speiser, Pu Yan, Erik Goormaghtigh.